Colgate-Palmolive Company is an American company specializing in the manufacturing and marketing of cleaning and hygiene products such as detergents, soaps, toothpaste and toothbrushes. The brand is enjoying a strong reputation in many countries.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
For the fiscal year ended December 31, 2002
OR
For the transition period from to .
Commission File Number 1-644
(Exact name of registrant as specified in its charter)
DELAWARE
13-1815595
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
300 Park Avenue, New York, New York
10022
(Address of principal executive offices)
(Zip Code)
Registrants telephone number, including area code 212-310-2000
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
$4.25 Preferred Stock, without par value,
New York Stock Exchange
cumulative dividend
Common Stock, $1.00 par value
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes X No
The aggregate market value of Colgate-Palmolive Common Stock held by non-affiliates as of June 28, 2002, (the last business day of our most recently completed second quarter) was approximately $26.8 billion.
There were 537,271,633 shares of Common Stock outstanding as of February 28, 2003.
DOCUMENTS INCORPORATED BY REFERENCE:
Documents
Form 10-K Reference
Portions of Proxy Statement for the2003 Annual Meeting
Part III, Items 10 through 13
PART I
ITEM 1. BUSINESS
(a) General Development of the Business
Colgate-Palmolive Company (together with its subsidiaries, the Company or Colgate), which was founded in 1806 and incorporated under the laws of the State of Delaware in 1923, is a leading consumer products company whose products are marketed in over 200 countries and territories throughout the world.
For recent business developments, refer to the information set forth in Part II, Item 7 of this report and Note 14 to the Consolidated Financial Statements.
(b) Financial Information about Industry Segments
Worldwide net sales and earnings by business segment and geographic region during the last three years appear under the caption Results of Operations in Part II, Item 7 of this report and Note 14 to the Consolidated Financial Statements.
(c) Narrative Description of the Business
The Company manages its business in two distinct product segments: Oral, Personal, Household Surface and Fabric Care; and Pet Nutrition. Colgate is a global leader in Oral Care with the leading toothpaste brand in the U.S. and throughout many parts of the world. Colgates Oral Care products include toothbrushes, toothpaste, tooth whitener, mouth rinses and dental floss, and pharmaceutical products for dentists and other oral health professionals. Significant recent product launches in this segment include Colgate Simply White at-home tooth whitening gel, Colgate 2in1 toothpaste and mouthwash, Colgate Total Plus Whitening, Colgate Herbal, Colgate Triple Action and Colgate Fresh Confidence toothpastes, and the Colgate Motion battery-powered toothbrush.
Colgate is a leader in many segments of the Personal Care market with several products including bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants and shave products. Colgate is the market leader in liquid soaps in the U.S. and in male deodorant sticks globally. Significant recent product launches in this segment include the Softsoap and Palmolive brands of body washes and liquid hand soaps such as Softsoap Vitamins shower gel and liquid hand soap, and Palmolive Aromatherapy shower gel, bath foam and liquid hand soap. Colgate also manufactures and markets Mennen underarm antiperspirants and deodorants and mens toiletries.
Colgate manufactures and markets a wide array of products for Household Surface and Fabric Care. Major products include Palmolive and Ajax dishwashing liquid and Fabuloso household cleansers. Colgate also markets other household names in cleaning and laundry products in the U.S. such as Fab and Murphys oil soap. In the Companys major markets outside the U.S., Colgate is number one in fabric conditioners with leading brands Suavitel in Latin America and Soupline in Europe. Significant recent product launches in this segment include Palmolive Spring Sensations dishwashing liquid, Ajax wipes and new variants of Ajax Fête des Fleurs cleaner.
Sales of Oral, Personal, Household Surface and Fabric Care products accounted for 34%, 24%, 16% and 13% of total worldwide sales in 2002, respectively. Geographically, Oral Care is a significant part of the Companys business in Asia/Africa, comprising approximately 51% of sales in that region for 2002. For more information regarding the Companys worldwide sales by product categories, refer to Notes 1 and 14 to the Consolidated Financial Statements included herein.
Colgate, through its Hills Pet Nutrition subsidiary, is the world leader in specialty pet nutrition products for dogs and cats. Hills markets pet foods primarily under two trademarks: Science Diet, which is sold by
2
authorized pet supply retailers, breeders and veterinarians for every day nutritional needs; and Prescription Diet for dogs and cats with disease conditions. Significant recent product launches in this segment include Science Diet Canine and Feline Oral Care, Prescription Diet Canine b/d formula that reduces the effects of canine brain aging, and Prescription Diet Canine and Feline z/d for allergic animals. Hills sells its products in 86 countries and leads the premium pet food segment in North America, Japan and South Africa. Sales of Pet Nutrition products accounted for 13% of the Companys total worldwide sales in 2002.
Research and Development
Strong research and development capabilities enable Colgate to support its many brands with technologically sophisticated products for consumers personal and household care and pet nutrition needs. Company spending related to research and development activities was $196.6 million, $184.9 million and $176.1 million during 2002, 2001 and 2000, respectively.
Distribution; Competition; Trademarks and Patents
The Companys products are generally marketed by a direct sales force at each individual operating subsidiary or business unit. In some instances, distributors or brokers are used. No single customer accounts for as much as 10% of the Companys sales.
Most raw materials are purchased from other companies and are available from several sources. Raw material commodities such as tallow and essential oils are subject to wide price variations. No single raw material represents a significant portion of the Companys total material requirements.
The Companys products are sold in a highly competitive global marketplace which is experiencing increased trade concentration. Products similar to those produced and sold by the Company are available from competitors in the U.S. and overseas. Certain of the Companys competitors are larger and have greater resources than the Company. In addition, private label brands sold by retail trade chains are becoming a source of competition for certain product lines of the Company. Product quality, brand recognition and acceptance and marketing capability largely determine success in the Companys business segments.
Trademarks are considered to be of material importance to the Companys business. The Company follows a practice of seeking trademark protection by all available means in the United States and throughout the world where the Companys products are sold. Principal global trademarks include Colgate, Palmolive, Kolynos, Sorriso, Mennen, Protex, Ajax, Soupline, Suavitel, Fab, Science Diet and Prescription Diet in addition to several regional trademarks. These trademarks are of significant importance to the Company and its subsidiaries within their markets. The Companys rights in these trademarks endure for as long as they are used and registered. Although the Company actively develops and maintains a number of patents, no single patent is considered significant to the business as a whole.
Employees
At year-end, the Company employed 37,700 employees of which 83% were located outside the United States.
Environmental Matters
It is the Companys policy to fully comply with environmental rules and regulations. Capital expenditures for environmental control facilities totaled $27.5 million for 2002. For future years, expenditures are expected to be in the same range. The Company has programs that are designed to ensure that its operations and facilities meet or exceed applicable rules and regulations. For information regarding other environmental matters refer to Note 13 to the Consolidated Financial Statements included herein.
3
(d) Financial Information about Foreign and Domestic Operations and Export Sales
For information concerning geographic area financial data refer to the information set forth under the caption Results of Operations in Part II, Item 7 of this report and in Note 14 to the Consolidated Financial Statements.
(e) Available Information
The Companys Internet address is www.colgate.com. The information contained on the Companys website is not included as a part of, or incorporated by reference into, this Annual Report on Form 10-K. The Company makes available, free of charge, on its Internet website, its annual report on Form 10-K, its quarterly reports on Form 10-Q, its current reports on Form 8-K and amendments to such reports filed or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934 as soon as reasonably practicable after the Company has electronically filed such material with, or furnished it to, the United States Securities and Exchange Commission.
ITEM 2. PROPERTIES
The Company owns and leases a total of 275 properties which include manufacturing, distribution, research and office facilities worldwide. Corporate headquarters is located in leased property at 300 Park Avenue, New York, New York.
In the U.S., the Company operates 29 properties, of which 11 are owned. Major U.S. manufacturing and warehousing facilities used by the Oral, Personal, Household Surface and Fabric Care segment are located in Kansas City, Kansas; Morristown, New Jersey; Jeffersonville, Indiana; and Cambridge, Ohio. The Pet Nutrition segment has major facilities in Bowling Green, Kentucky; Topeka, Kansas; Commerce, California; and Richmond, Indiana. The primary research center for Oral, Personal, Household Surface and Fabric Care products is located in Piscataway, New Jersey and the primary research center for Pet Nutrition products is located in Topeka, Kansas. Other research facilities are located in select overseas locations.
Overseas, the Company operates 246 properties, of which 88 are owned, in over 70 countries. Major overseas facilities used by the Oral, Personal, Household Surface and Fabric Care segment are located in Australia, Brazil, Canada, China, Colombia, France, Italy, Malaysia, Mexico, South Africa, Thailand, the United Kingdom, Venezuela and elsewhere throughout the world. In some areas outside the U.S., products are either manufactured by independent contractors under Company specifications or are imported from the U.S. or elsewhere.
All facilities operated by the Company are, in general, well maintained and adequate for the purpose for which they are intended. The Company conducts continuing reviews of its facilities with the view to modernization and cost reduction.
ITEM 3. LEGAL PROCEEDINGS
In 1995, the Company acquired the Kolynos oral care business from Wyeth (formerly American Home Products) (the Seller), as described in the Companys Form 8-K dated January 10, 1995. On September 8, 1998, the Companys Brazilian subsidiary received notice of an administrative proceeding from the Central Bank of Brazil primarily taking issue with certain foreign exchange filings made with the Central Bank in connection with the financing of this strategic transaction, but in no way challenging or seeking to unwind the acquisition. The Central Bank of Brazil in January 2001 notified the Company of its decision in this administrative proceeding to impose a fine, which, at the current exchange rate, approximates $75 million. The Company has appealed the decision to the Brazilian Monetary System Appeals Council (the Council), thereby suspending the fine pending the decision of the Council. If the fine is affirmed, interest and penalties may also be assessed. Further appeals are available within the Brazilian federal courts. Management believes, based on the opinion of
4
its Brazilian legal counsel and other experts, that the filings challenged by the Central Bank fully complied with Brazilian law and that the Company will prevail on appeal. The Company intends to challenge this fine vigorously. In addition, Brazilian prosecutors are reviewing the foregoing transactions as part of an overall examination of all international transfers of Reais through non-resident current accounts during the 1992 to 1998 time frame. The Company understands that this examination involves hundreds and possibly thousands of other individuals and companies. In 2002 the Brazilian Federal Public Attorney filed a civil action against the federal government of Brazil, Laboratorios Wyeth-Whitehall Ltda., the Brazilian subsidiary of the Seller, and the Company, as represented by its Brazilian subsidiary, seeking to annul an April 2000 decision by the Brazilian Board of Tax Appeals that found in favor of the Sellers subsidiary on the issue of whether it had incurred taxable capital gains as a result of the divestiture of Kolynos. The action seeks to make the Companys Brazilian subsidiary jointly and severally liable for any tax due from the Sellers subsidiary. Management believes, based on the opinion of its Brazilian legal counsel, that the Company will ultimately prevail in this action. The Company intends to challenge this action vigorously.
In addition, the Brazilian internal revenue authority has disallowed interest deductions and foreign exchange losses taken by the Companys Brazilian subsidiary in connection with the financing of the Kolynos acquisition, imposing a tax assessment which has been determined, at the current exchange rate, to approximate $30 million. The Company has filed an administrative appeal with the Brazilian internal revenue authority, and further appeals are available within the Brazilian federal courts. Management believes, based on the opinion of its Brazilian legal counsel and other experts, that the disallowance is without merit and that the Company will prevail on appeal. The Company intends to challenge this assessment vigorously.
For information regarding other legal matters refer to Note 13 to the Consolidated Financial Statements.
5
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
EXECUTIVE OFFICERS OF THE REGISTRANT
The following is a list of executive officers as of March 21, 2003:
Name
Age
Date First Elected Officer
Present Title
Reuben Mark
64
1974
Chairman of the Board and Chief Executive Officer
William S. Shanahan
62
1983
President
Lois D. Juliber
54
1991
Chief Operating Officer
Javier G. Teruel
52
1996
Executive Vice President
Ian M. Cook
50
Stephen C. Patrick
53
1990
Chief Financial Officer
Andrew D. Hendry
55
Senior Vice President
General Counsel and Secretary
Michael J. Tangney
58
1993
President, Colgate-Latin America
Robert J. Joy
56
Global Human Resources
Dennis J. Hickey
1998
Vice President and
Corporate Controller
Robert C. Wheeler
61
Chief Executive Officer
Hills Pet Nutrition, Inc.
Steven R. Belasco
Vice President
Taxation and Real Estate
Ronald T. Martin
2001
Global Business Practices and Public Affairs
John J. Huston
48
2002
Office of the Chairman
Franck J. Moison
49
President, Colgate-Europe
Delia H. Thompson
Vice President, Investor Relations
Each of the executive officers listed above has served the registrant or its subsidiaries in various executive capacities for the past five years.
Under the Companys By-Laws, the officers of the corporation hold office until their respective successors are chosen and qualified, or until they have resigned, retired or been removed by the affirmative vote of a majority of the Board of Directors.
6
PART II
Refer to the information regarding the market for the Companys common stock and the quarterly market price information appearing under the caption Market and Dividend Information included on page 53 of this report; the information under Capital Stock and Stock Compensation Plans in Note 8 to the Consolidated Financial Statements; and the Number of shareholders of record and Cash dividends declared and paid per common share under the caption Historical Financial Summary included on page 54 of this report.
Refer to the information set forth under the caption Historical Financial Summary included on page 54 of this report.
(Dollars in Millions Except Per Share Amounts)
The Company manufactures and markets its products in over 200 countries and territories throughout the world in two distinct business segments: Oral, Personal, Household Surface and Fabric Care; and Pet Nutrition. Segment performance is evaluated based on several factors, including operating profit. The Company uses operating profit as a measure of the basic health of the operating segments because it excludes the impact of corporate-driven decisions related to interest expense and income taxes.
Prior years segment information has been revised for new accounting requirements and certain reclassifications. Net sales were revised for the impact of the new accounting for sales incentives described in Note 2 to the Consolidated Financial Statements, with no effect on operating profit or net income. As is also described in Note 2, the Company changed its accounting for goodwill and other intangible assets in 2002. In accordance with the new standard, prior periods were not restated. Amounts for certain businesses in the Caribbean, which were previously reported in Latin America, have been reclassified to North America to conform with current year presentation and change in management responsibilities.
Results of Operations
2000
Worldwide Net Sales by Business Segment and Geographic Region
Oral, Personal, Household Surface and Fabric Care
North America(1)
$
2,374.1
2,299.9
2,216.5
Latin America
2,206.8
2,356.0
2,406.6
Europe
1,984.3
1,835.0
1,825.8
Asia/Africa
1,542.0
1,484.3
1,496.6
Total Oral, Personal, Household Surface and Fabric Care
8,107.2
7,975.2
7,945.5
Total Pet Nutrition(2)
1,187.1
1,109.1
1,058.9
Net Sales
9,294.3
9,084.3
9,004.4
7
Worldwide net sales increased 2.5% to $9,294.3 in 2002 on volume growth of 4.5%. Net sales would have grown 5.0% excluding foreign currency translation. Net sales in the Oral, Personal, Household Surface and Fabric Care segment increased 2.0%, excluding divestitures, on 4.5% volume growth; while net sales in Pet Nutrition increased by 7.0% on 5.5% volume growth. In 2001, worldwide net sales, excluding divestitures, increased 2.0% to $9,084.3 on volume growth of 5.0%, reflecting the negative impact of foreign currency translation.
Gross Profit
Gross profit margin increased to 54.6%, above both the 2001 level of 53.4% and the 2000 level of 52.7%. This favorable trend reflects the Companys strategy to improve all aspects of its supply chain through global sourcing, regionalization of manufacturing facilities and other cost-reduction initiatives, as well as its emphasis on higher margin products.
Selling, General and Administrative Expenses
Selling, general and administrative expenses as a percentage of sales were 32.6% in 2002, 32.1% in 2001 and 32.8% in 2000. The increase in 2002 was primarily driven by pension and other employee benefit costs that were partially offset by the benefit of ongoing cost-savings initiatives. In 2001, the overall spending as a percentage of sales decreased as a result of the Companys ongoing focus on overhead reduction and the effect of translation on local currency costs. Total advertising support behind Colgate brands, including media, promotion and other consumer and trade incentives, some of which reduce reported sales, has increased by 8%, 1% and 3% in 2002, 2001 and 2000, respectively. Included in selling, general and administrative expenses is media spending of $486.6, $509.0 and $550.9 in 2002, 2001 and 2000, respectively. The trend in media spending reflects lower media pricing, the negative impact of foreign exchange and a slight shift in investment to other forms of total advertising support.
Other Expense, Net
Other expense, net, consists principally of minority interest in earnings of less-than-100%-owned consolidated subsidiaries, amortization of intangible assets, earnings from equity investments, gains and losses on interest rate and foreign currency hedge contracts that do not qualify for hedge accounting, and other miscellaneous gains and losses.
During 2002, other expense, net, decreased from $94.5 to $23.0 resulting from the benefit of the change in accounting for goodwill and intangible assets and changes in the fair value of foreign currency contracts. These contracts are an economic hedge of certain foreign currency debt but do not qualify for hedge accounting. During 2001, other expense, net, increased from $52.3 to $94.5 primarily due to changes in the fair value of foreign currency contracts. During 2000, the Company recorded charges of $92.7 ($61.2 aftertax) in other expense, net, including a restructuring charge related to the realignment of certain manufacturing operations and the exiting of its business in Nigeria. Also included were gains of $102.0 ($60.9 aftertax) recorded on the sale of real estate and the sale of the Viva detergent brand in Mexico.
Operating Profit
Operating profit rose 10% to $2,013.1 in 2002 from $1,834.8 in 2001, which had reflected a 5% increase from 2000 operating profit of $1,740.5. The continued increase resulted from strong volume growth and cost-saving initiatives. If prior year results were adjusted for the impact of the change in accounting for goodwill and intangible assets, operating profit would have been $1,889.1 and $1,800.2 for 2001 and 2000, respectively.
Interest Expense, Net
Interest expense, net, was $142.8 compared with $166.1 in 2001 and $173.3 in 2000. This decreasing trend is the result of lower interest rates partially offset by increased average debt levels related to share repurchases during the year.
8
Income Taxes
The effective tax rate on income was 31.1% in 2002 versus 31.3% in 2001 and 32.1% in 2000. If 2001 and 2000 had been adjusted for the impact of the change in accounting for goodwill and intangible assets, the respective tax rates would have been 30.9% and 31.7%. Global tax planning strategies, including the realization of tax credits and incentives, reduced the effective tax rate in all three years presented.
Net Income
Net income was $1,288.3 in 2002 or $2.19 per share on a diluted basis compared with $1,146.6 in 2001 or $1.89 per share and $1,063.8 in 2000 or $1.70 per share. If results for 2001 and 2000 were adjusted for the impact of the change in accounting for goodwill and intangible assets, net income and diluted earnings per share would have been $1,190.4 and $1.96, respectively, for 2001 and $1,111.6 and $1.77, respectively, for 2000.
Segment Results
Worldwide Operating Profit by Business Segment andGeographic Region
North America
578.7
516.6
487.9
647.4
663.2
597.6
409.0
342.6
320.0
232.6
195.9
194.0
1,867.7
1,718.3
1,599.5
Total Pet Nutrition
318.3
282.1
243.5
Total Corporate
(172.9
)
(165.6
(102.5
2,013.1
1,834.8
1,740.5
North America net sales grew 3.0% to $2,374.1 on volume gains of 6.0%. Volume increases were led by the strength of recently introduced products in all core categories. In the Oral Care category, innovative products such as Colgate Simply White at-home tooth whitening gel, Colgate Total Plus Whitening toothpaste, Colgate 2 in 1 toothpaste and mouthwash and the Colgate Motion battery-powered toothbrush contributed to increased volume and market share. The Personal Care category experienced incremental market share driven by volume gains from recently introduced products such as Softsoap Aromatherapy body wash and liquid hand soap, Irish Spring Vitamins deodorant bar soap and Mennen Speed Stick Power of Nature deodorant. The Household Surface Care category had increased volumes from products such as Palmolive Aromatherapy hand dishwashing liquid. In 2001, North America achieved overall sales growth of 4.0% to $2,299.9 on volume growth of 4.5%.
Operating profit in North America grew 12% to $578.7 as a result of volume gains, emphasis on higher margin products, and cost-savings initiatives improving gross profit margin. The impact of the discontinuation of amortization of goodwill and indefinite life intangible assets in 2002 was largely offset by increased pension and benefit costs. Operating profit in 2001 increased 6% to $516.6, reflecting volume growth and efficiencies in advertising spending.
9
Net sales in Latin America declined 5.5%, excluding divestitures, to $2,206.8 on 2.5% volume growth offset by the negative effect of foreign currency primarily in Venezuela, Argentina and Brazil. The strongest volume gains in the region were achieved in Mexico, Ecuador, Colombia, Venezuela and the Dominican Republic. Recently launched products including Colgate Fresh Confidence Xtreme Red Gel, Colgate Total Plus Whitening, Colgate Triple Action, Sorriso Jua + Propolis toothpastes, and Colgate Premier Ultra and Colgate Active Flexible manual toothbrushes contributed to increased volume and market share in the Oral Care category throughout the region. Other products contributing to volume gains in the region were Palmolive Naturals bar soaps, Palmolive Naturals and Caprice hair care lines, Mennen Speed Stick Power of Nature deodorant and Fabuloso Vibrante Naturaleza liquid cleaners in the Personal and Household Surface Care categories. In 2001, Latin America net sales declined 2.0% to $2,356.0 as volume gains of 5.0% were negatively impacted by foreign exchange.
Operating profit in Latin America decreased 2% to $647.4 as the negative effect of foreign currency offset volume growth, cost-control initiatives, and the discontinuation of amortization of goodwill and indefinite life intangible assets in 2002. Operating profit in 2001 increased 11% to $663.2 as a result of volume gains, higher gross profit margins, ongoing cost containment and efficiencies in advertising spending.
Net sales in Europe increased 8.0% to $1,984.3 on unit volume gains of 5.0% and the impact of the stronger Euro. The United Kingdom, Russia, Turkey, France and Greece achieved the strongest volume increases in the region. New products including Colgate Total Plus Whitening toothpaste and Colgate 2 in 1 toothpaste and mouthwash contributed to regional volume growth in the Oral Care category. In the Personal, Household Surface and Fabric Care categories, new products such as Palmolive Aromatherapy shower gel, foam bath and liquid hand soap, Palmolive Soft & Gentle deodorant, Soupline Lily of the Valley fabric conditioner and Ajax Wipes contributed to increased volumes and market share. In 2001, Europe net sales increased 1.0%, excluding divestitures, to $1,835.0, on volume growth of 5.5%, partially offset by the weakened Euro.
Operating profit in Europe increased 19% to $409.0 as a result of volume growth, gross margin improvement, the impact of the stronger Euro, and the discontinuation of amortization of goodwill and indefinite life intangible assets. Operating profit in 2001 increased 7%, excluding divestitures, to $342.6 due to volume gains and higher gross profit margins.
Net sales in Asia/Africa increased 4.0% to $1,542.0 on volume gains of 4.5% offset by the impact of foreign currencies. The Philippines, China, South Africa and Australia achieved the strongest volume gains in the region. New products including Colgate Herbal and Colgate Triple Action toothpastes, and Colgate Active Flexible and Colgate Extra Clean manual toothbrushes contributed to volume gains in the Oral Care category. In the Personal and Household Surface Care categories, recently introduced products such as Protex Herbal antibacterial bar soap and talc, Palmolive Naturals shampoo and Ajax Fêtes des Fleurs liquid cleaner helped to drive volume growth in the region. In 2001, net sales in Asia/Africa declined 1.0% to $1,484.3 as volume gains of 6.0% were offset by foreign currency weakness.
Operating profit grew 19% in Asia/Africa to $232.6 in 2002 and 1% to $195.9 in 2001, driven by volume gains and higher gross profit margins benefiting from regionalization of manufacturing facilities.
Pet Nutrition
Net sales for Hills Pet Nutrition increased 7.0% to $1,187.1 on 5.5% volume growth. North American sales increased due to the introduction of innovative new products including Science Diet Natures Best, a line of
10
natural cat and dog food. Hills also experienced strong volume growth in Europe, South Pacific and Asia driven by new products such as Prescription Diet Canine b/d, a clinically proven product that reduces the signs of canine brain aging. In 2001, net sales for the Pet Nutrition segment increased 4.5% to $1,109.1 on 5.5% volume gains.
Operating profit in Pet Nutrition grew 13% to $318.3 in 2002 and 16% to $282.1 in 2001 as a result of strong volume gains and higher gross profit margins, as well as ongoing cost-savings initiatives.
Liquidity and Capital Resources
Net cash provided by operations increased 7% to $1,611.2 compared with $1,503.9 in 2001 and $1,536.2 in 2000. The increase reflects the Companys improved profitability and working capital management partially offset by higher cash taxes, a portion of which related to a deferral of 2001 taxes into 2002 under a government relief program as a result of the events of September 11, 2001. The decrease in 2001 reflected voluntary contributions to employee benefit plans and higher cash taxes. Cash taxes in 2000 were reduced by certain tax credits that have been fully utilized. Cash generated from operations was used to fund capital spending, pay increased dividends and repurchase common shares. Voluntary contributions to benefit plans made in 2001 were reclassified in the Consolidated Statements of Cash Flows from investing activities to operating activities consistent with current year presentation.
Capital expenditures were 4% of net sales for 2002, 2001 and 2000. Capital spending continues to be focused primarily on projects that yield high aftertax returns. Capital expenditures for 2003 are expected to continue at the current rate of approximately 4% of net sales.
In 2000, other investing activities included acquisitions with an aggregate purchase price of $64.9. There were no significant acquisitions in 2002 or 2001. Certain detergent product lines in Central America were sold in 2001 and the Mexico Viva detergent brand was sold in 2000. The aggregate sale price of all 2001 and 2000 sales of brands was $12.5 and $102.5, respectively. There were no significant divestitures in 2002.
During 2002, long-term debt increased to $3,509.3 from $3,137.5 and total debt increased to $3,603.9 from $3,239.1, primarily due to continued share repurchases and the impact of translating debt denominated in Euros. The Companys long-term debt rating was upgraded in 2001 to AA- by Standard & Poors and Aa3 by Moodys.
Domestic and foreign commercial paper outstanding was $391.4 and $605.8, as of December 31, 2002 and 2001, respectively. These borrowings carry a Standard & Poors rating of A1+ and a Moodys rating of P1. The commercial paper and certain current maturities of notes payable are classified as long-term debt at December 31, 2002, as the Company has the intent and ability to refinance such obligations on a long-term basis.
Certain of the Companys financing arrangements require the maintenance of a minimum ratio of operating cash flow to debt. The ESOP notes guaranteed by the Company and certain amounts payable to banks contain cross-default provisions. Noncompliance with these requirements could ultimately result in the acceleration of amounts owed. The Company is in full compliance with all such requirements and believes the likelihood of noncompliance is remote.
In 1993, the Company formed a financing subsidiary with outside equity investors that purchases some of the Companys receivables. The Company consolidates this entity, including such receivables, and reports the amounts invested by outside investors as a minority interest. The purpose of this arrangement is to provide the Company access to low-cost sources of capital. During 2000, this subsidiary ceased operations resulting in a cash payment of $113.9 to the outside investors. In 2001, the subsidiary resumed operations with funding of $89.7 from outside investors.
The Company repurchases common shares in the open-market and in private transactions for employee benefit plans and to maintain its targeted capital structure. Aggregate repurchases for 2002 were 20.0 million
11
shares, with a total purchase price of $1,082.9. In 2001 and 2000, 21.7 million and 19.1 million shares were repurchased, respectively, with total purchase prices of $1,230.2 and $1,040.6, respectively.
Dividend payments were $413.4, up from $396.7 in 2001 and $382.4 in 2000. Common stock dividend payments increased to $.72 per share in 2002 from $.68 per share in 2001 and $.63 per share in 2000. The Series B Preference Stock dividend payments were increased to $5.76 per share in 2002 from $5.40 per share in 2001 and $5.04 in 2000. The Company recently increased the annualized common stock dividend to $.96 per share and the annualized Series B Preference Stock dividend to $7.68 per share effective in the second quarter of 2003.
Internally generated cash flows are adequate to support currently planned business operations and capital expenditures. Free cash flow (defined as cash generated by the business after capital expenditures and dividend payments but before acquisitions, divestitures and share repurchases) was $854.1, $767.0 and $787.2 in 2002, 2001 and 2000, respectively, and provides the Company with flexibility for further investments and/or financing. The Company has additional sources of liquidity available in the form of lines of credit maintained with various banks and access to financial markets worldwide.
At December 31, 2002, the Company had access to unused lines of credit of $2,082.6 and also had $586.8 available under medium-term notes.
The following represents the scheduled maturities of the Companys long-term contractual obligations as of December 31, 2002.
Payments Due by Period
Total
2003
2004
2005
2006
2007
Thereafter
Long-term debt including current portion
3,459.1
(1)
308.2
400.4
266.3
247.7
1,127.4
Capitalized leases
50.2
4.9
5.1
5.4
5.6
5.8
23.4
Operating leases
387.6
72.3
62.7
55.8
49.7
48.8
98.3
Unconditional purchaseobligations
108.2
71.5
35.5
1.2
4,005.1
1,257.8
411.5
462.8
321.6
302.3
1,249.1
The Company does not have off-balance sheet financing or unconsolidated special purpose entities. The Companys treasury and risk management policies prohibit the use of leveraged derivatives or derivatives for trading purposes. The valuations of financial instruments that are marked to market are based upon independent third-party sources including quoted market prices.
As more fully described in Note 13 to the Consolidated Financial Statements, the Company is party to various superfund and other environmental matters in connection with prior acquisitions. Substantially all of these liabilities have been acknowledged in writing as being covered by investment-grade insurance carriers that are presently making all their required payments directly to the cleanup efforts and are expected to do so in the future. The Company is also contingently liable with respect to lawsuits, taxes and other matters arising out of the normal course of business. It is the opinion of management that the ultimate disposition of these matters, to the extent not previously provided for, will not have a material impact on the financial position, results of operations or ongoing cash flows of the Company.
12
Restructuring Reserves
In December 2000, the Company recorded a charge of $63.9 ($42.5 aftertax) associated with the realignment of three manufacturing locations in Latin America and the exiting of its business in Nigeria. The charge recorded included $14.2 for termination costs and $49.7 for exiting of manufacturing operations. The restructuring was completed in 2001.
Managing Foreign Currency, Interest Rate and Commodity Price Exposure
The Company is exposed to market risk from foreign currency exchange rates, interest rates and commodity price fluctuations. Volatility relating to these exposures is managed on a consolidated basis by utilizing a number of techniques, including working capital management, selective borrowings in local currencies and entering into certain derivative instrument transactions in accordance with the Companys treasury and risk management policies. The Companys treasury and risk management policies prohibit the use of leveraged derivatives or derivatives for trading purposes.
With operations in over 200 countries and territories, the Company is exposed to currency fluctuation related to manufacturing and selling its products in currencies other than the U.S. Dollar. The major foreign currency exposures involve the markets in the European Union and certain Latin American countries, although all regions of the world are subject to foreign currency changes versus the U.S. Dollar. The Company actively monitors its foreign currency exposures in these markets and has been able to substantially offset the impact on earnings of foreign currency rate movements through a combination of cost-containment measures, foreign currency hedging activities and selling price increases.
The Company primarily utilizes currency forward and swap contracts to hedge portions of its exposures relating to foreign currency purchases and assets and liabilities created in the normal course of business. From time to time, the Company hedges certain of its forecasted foreign currency purchases using forward contracts with durations no greater than 18 months.
Interest rate swaps and debt issuances are utilized to manage the Companys targeted mix of fixed and floating rate debt and to minimize significant fluctuations in earnings and cash flows that may result from interest rate volatility.
The Company is exposed to price volatility related to raw materials used in production. Futures and option contracts are used on a limited basis to manage volatility related to anticipated raw material inventory purchases. The results of the Companys commodity hedging activities are not material.
The Company is exposed to credit loss in the event of nonperformance by counterparties to the financial instrument contracts held by the Company; however, nonperformance by these counterparties is considered remote as it is the Companys policy to contract with diversified counterparties that have a long-term debt rating of A or higher.
Value at Risk
The Companys risk management procedures include the monitoring of interest rate and foreign exchange exposures and hedge positions utilizing statistical analyses of cash flows, market value and sensitivity analysis. However, the use of these techniques to quantify the market risk of such instruments should not be construed as an endorsement of their accuracy or the accuracy of the related assumptions. Market exposures are evaluated using a value-at-risk (VAR) model and an earnings-at-risk (EAR) model that are intended to measure the maximum potential loss in interest rate and foreign exchange financial instruments, assuming adverse market conditions occur, given a 95% confidence level. The models utilize a variance/covariance modeling technique.
13
Historical interest rates and foreign exchange rates from the preceding year are used to estimate the volatility and correlation of future rates.
The estimated maximum potential one-day loss in fair value of interest rate or foreign exchange rate instruments, calculated using the VAR model, is not material to the consolidated financial position, results of operations or cash flows of the Company in 2002 and 2001. The estimated maximum yearly loss in earnings due to interest rate or foreign exchange rate instruments, calculated utilizing the EAR model, is not material to the Companys results of operations in 2002 and 2001. Actual results in the future may differ materially from these projected results due to actual developments in the global financial markets.
For information regarding the Companys accounting policies for financial instruments and a description of financial instrument activities, refer to Note 2 and Note 7 to the Consolidated Financial Statements.
Recent Accounting Pronouncements
On January 1, 2002, the Company adopted the Financial Accounting Standards Boards (FASB) Emerging Issues Task Force (EITF) Issue No. 00-14, Accounting for Certain Sales Incentives, and Issue No. 00-25, Vendor Income Statement Characterization of Consideration Paid to a Reseller of the Vendors Products, that relate to the classification of various types of sales incentives and promotional expenses. The Consolidated Statements of Income for 2001 and 2000 have been revised to reflect the reclassification of certain sales incentives and promotional expenses from selling, general and administrative expenses to a reduction of net sales and cost of sales; however, the revisions had no impact on the Companys financial position, net income or earnings per share. These reclassifications reduced net sales by $343.5 and $353.5 and cost of sales by $2.0 and $8.5 for the years ended December 31, 2001 and 2000, respectively, with an offsetting reduction in each period in selling, general and administrative expenses.
On January 1, 2002, the Company adopted Statement of Financial Accounting Standards (SFAS) No. 142, Goodwill and Other Intangible Assets, which eliminates the amortization of goodwill and indefinite life intangible assets but requires annual impairment reviews. In accordance with SFAS No. 142, prior period amounts were not restated. A reconciliation of previously reported net income, basic earnings per share and diluted earnings per share for 2001 and 2000 to the amounts adjusted to exclude goodwill and indefinite life intangible assets amortization is presented in Note 2 to the Consolidated Financial Statements.
Refer to Note 2 to the Consolidated Financial Statements for further discussion of recent accounting pronouncements.
Critical Accounting Policies and Use of Estimates
The preparation of financial statements requires management to use judgment and make estimates. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. Actual results could ultimately differ from those estimates. The accounting policies that are most critical in the preparation of the Companys Consolidated Financial Statements are those that are both important to the portrayal of the Companys financial condition and results of operations and require significant or complex judgments and estimates on the part of management. The Companys critical accounting policies have been reviewed with the Audit Committee of the Board of Directors.
In certain instances, accounting principles generally accepted in the United States of America allow for the selection of alternative accounting methods. The Companys significant policies that involve the selection of alternative methods are accounting for stock options, shipping and handling costs, and inventories.
14
The areas of accounting that involve significant or complex judgments and estimates are pensions and other postretirement benefits, asset impairment, tax valuation allowances, and legal and other contingencies.
The Company generates revenue through the sale of well-known consumer products to trade customers under established trading terms. While the recognition of revenue and receivables requires the use of estimates, there is a short time frame (typically less than 60 days) between the shipment of product and cash receipt, thereby reducing the level of uncertainty in these estimates. (Refer to Note 2 to the Consolidated Financial Statements for further description of the Companys significant accounting policies.)
15
Outlook
Looking forward into 2003, the Company is well positioned for continued growth in most of its markets. However, the Company operates in a highly competitive global marketplace that is experiencing increased trade concentration. In addition, movements in foreign currency exchange rates can impact future operating results as measured in U.S. Dollars. In particular, economic uncertainty in some countries in Latin America and changes in the value of the Euro may impact the overall results of Latin America and Europe.
The Company expects the continued success of Colgate toothpaste, using patented and proprietary technology, to bolster worldwide Oral Care leadership and expects new products in Oral Care and other categories to add potential for further growth. Overall, subject to global economic conditions, the Company does not expect the 2003 market conditions to be materially different from those experienced in 2002 and the Company expects its positive momentum to continue.
Historically, the consumer products industry has been less susceptible to changes in economic growth than many other industries. Therefore, the Company constantly evaluates projects that will focus operations on opportunities for enhanced growth potential. Over the long term, Colgates continued focus on its consumer products business and the strength of its global brand names, its broad international presence in both developed and developing markets, and its strong capital base all position the Company to take advantage of growth opportunities and to continue to increase profitability and shareholder value.
Cautionary Statement on Forward-Looking Statements
In this report and from time to time, the Company may make statements that constitute or contain forward-looking information as that term is defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases. Such statements may relate, for example, to sales or volume growth, earnings growth, financial goals, cost-reduction plans and new product introductions among other matters. The Company cautions investors that any such forward-looking statements made by the Company are not guarantees of future performance and that actual results may differ materially from anticipated results or expectations expressed in the Companys forward-looking statements. The following are some of the factors that could cause actual results to differ materially from forward-looking statements:
16
ITEM 7A. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK
See Managing Foreign Currency, Interest Rate and Commodity Price Exposure and Value at Risk located on page 13 of this report.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
See the Index to Financial Statements which is located on page 24 of this report.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
On May 16, 2002, the Company appointed PricewaterhouseCoopers LLP as the Companys independent public accountants. For additional information, refer to the Companys current report on Form 8-K, filed on May 17, 2002.
17
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Information regarding directors and executive officers of the registrant set forth in the Proxy Statement for the 2003 Annual Meeting is incorporated herein by reference, as is the text in Part I of this report under the caption Executive Officers of the Registrant.
ITEM 11. EXECUTIVE COMPENSATION
The information regarding executive compensation set forth in the Proxy Statement for the 2003 Annual Meeting is incorporated herein by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS
(c)
Equity Compensation Plan Information
(a)
(b)
Plan category
Number of securities to be issued upon exercise of outstanding options, warrants and rights
(in thousands)
Weighted-average exercise price of outstanding options, warrants and rights
Number of securitiesremaining available forfuture issuance under equity compensation plans (excluding securities reflected in
column (a))
Equity compensation plans approved by security holders
45,306(1)
$44(2)
15,936(3)
Equity compensation plans not approved by security holders
Not applicable
45,306
$44
15,936
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information regarding certain relationships and related transactions set forth in the Proxy Statement for the 2003 Annual Meeting is incorporated herein by reference.
18
PART IV
ITEM 14. CONTROLS AND PROCEDURES
Within the 90-day period prior to the date of this report, the Company, under the supervision and with the participation of the Companys management, including the Companys Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Companys disclosure controls and procedures (the Evaluation). Based upon the Evaluation, the Companys Chief Executive Officer and Chief Financial Officer concluded that the Companys disclosure controls and procedures are effective in ensuring that material information relating to the Company, including its consolidated subsidiaries, is made known to them by others within those entities, particularly during the period in which this annual report was being prepared. There were no significant changes in the Companys internal controls or in other factors that could significantly affect these controls subsequent to the date of the Evaluation.
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
On April 12, 2002, the Company filed a current report on Form 8-K including certain reclassified income statement information for 2001 and 2000 pursuant to new accounting requirements implemented by the Emerging Issues Task Force.
On May 17, 2002, the Company filed a current report on Form 8-K relating to the change in its certifying accountant.
On August 2, 2002, the Company filed a current report on Form 8-K attaching as exhibits sworn statements made by each of the Chairman and Chief Executive Officer and the Chief Financial Officer of the Company certifying previously filed reports pursuant to Securities and Exchange Commission Order No. 4-460.
19
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
COLGATE-PALMOLIVE COMPANY
(Registrant)
By:
/S/ REUBENMARK
Chairman of the Board
and Chief Executive Officer
Date: March 21, 2003
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 21, 2003 by the following persons on behalf of the registrant and in the capacities indicated.
(a) Principal Executive Officer
(c) Principal Accounting Officer
/S/ DENNIS J. HICKEY
(b) Principal Financial Officer
(d) Directors:
/S/ STEPHEN C. PATRICK
Jill K. Conway, Ronald E. Ferguson,
Carlos M. Gutierrez, Ellen M. Hancock,
David W. Johnson, Richard J. Kogan,
Delano E. Lewis, Reuben Mark,
Howard B. Wentz, Jr.
/S/ ANDREW D. HENDRY
as Attorney-in-Fact
20
CERTIFICATIONS
I, Reuben Mark, Chairman and Chief Executive Officer of Colgate-Palmolive Company, certify that:
Chairman and Chief Executive Officer
21
I, Stephen C. Patrick, Chief Financial Officer of Colgate-Palmolive Company, certify that:
22
United States
Securities and Exchange Commission
CONSOLIDATED FINANCIAL STATEMENTS
For The Year Ended December 31, 2002
NEW YORK, NEW YORK 10022
23
Index to Financial Statements
Page
Consolidated Financial Statements
Consolidated Statements of Income for the yearsended December 31, 2002, 2001 and 2000
25
Consolidated Balance Sheets as of December 31, 2002 and 2001
26
Consolidated Statements of Retained Earnings, Comprehensive Incomeand Changes in Capital Accounts for the years endedDecember 31, 2002, 2001 and 2000
27
Consolidated Statements of Cash Flows for the yearsended December 31, 2002, 2001 and 2000
28
Notes to Consolidated Financial Statements
29
Schedule IIValuation and Qualifying Accounts for the years endedDecember 31, 2002, 2001 and 2000
Reports of Independent Accountants
51
Selected Financial Data
Market and Dividend Information
Historical Financial Summary
All other financial statements and schedules not listed have been omitted since the required information is included in the financial statements or the notes thereto or is not applicable or required.
24
Consolidated Statements of Income
For the years ended December 31,
Net sales
Cost of sales
4,224.2
4,234.9
4,257.0
Gross profit
5,070.1
4,849.4
4,747.4
Selling, general and administrative expenses
3,034.0
2,920.1
2,954.6
Other expense, net
23.0
94.5
52.3
Operating profit
Interest expense, net
142.8
166.1
173.3
Income before income taxes
1,870.3
1,668.7
1,567.2
Provision for income taxes
582.0
522.1
503.4
Net income
1,288.3
1,146.6
1,063.8
Earnings per common share, basic
2.33
2.02
1.81
Earnings per common share, diluted
2.19
1.89
1.70
See Notes to Consolidated Financial Statements.
Consolidated Balance Sheets
As of December 31,
Assets
Current Assets
Cash and cash equivalents
167.9
172.7
Receivables (less allowances of $45.9 and $45.6, respectively)
1,145.4
1,124.9
Inventories
671.7
677.0
Other current assets
243.1
228.8
Total current assets
2,228.1
2,203.4
Property, plant and equipment, net
2,491.3
2,513.5
Goodwill, net
1,182.8
1,284.2
Other intangible assets, net
608.5
619.8
Other assets
576.5
363.9
Total assets
7,087.2
6,984.8
Liabilities and Shareholders Equity
Current Liabilities
Notes and loans payable
94.6
101.6
Current portion of long-term debt
298.5
325.5
Accounts payable
728.3
678.1
Accrued income taxes
121.7
195.0
Other accruals
905.6
823.3
Total current liabilities
2,148.7
2,123.5
Long-term debt
3,210.8
2,812.0
Deferred income taxes
488.8
480.6
Other liabilities
888.6
722.3
Shareholders Equity
Preferred stock
323.0
341.3
Common stock, $1 par value (1,000,000,000 shares authorized,732,853,180 shares issued)
732.9
Additional paid-in capital
1,133.9
1,168.7
Retained earnings
6,518.5
5,643.6
Accumulated other comprehensive income
(1,865.6
(1,491.2
6,842.7
6,395.3
Unearned compensation
(340.1
(345.4
Treasury stock, at cost
(6,152.3
(5,203.5
Total shareholders equity
350.3
846.4
Total liabilities and shareholders equity
Consolidated Statements of Retained Earnings, Comprehensive Income
and Changes in Capital Accounts
Dollars in Millions Except Per Share Amounts
Common Shares
Additional Paid-in Capital
Treasury Shares
Retained Earnings
Accumulated Other Compre-
hensive Income
Compre-
Shares
Amount
Balance, January 1, 2000
578,863,046
1,063.2
153,999,624
3,056.4
4,212.3
(1,136.2
Other comprehensive income:
Cumulative translation adjustment
(133.5
Total comprehensive income
930.3
Dividends declared:
Series B Convertible
Preference Stock, net of income taxes
(20.3
(.4
Common stock
(361.7
Shares issued for stock options
4,796,186
96.7
(4,796,186
54.3
Treasury stock acquired
(19,099,681
19,099,681
1,040.6
Other
2,096,323
(15.0
(2,084,163
(107.9
Balance, December 31, 2000
566,655,874
1,144.9
166,218,956
4,043.4
4,893.7
(1,269.7
(198.5
(23.0
925.1
(21.3
(375.0
2,705,887
62.4
(2,705,887
20.5
(21,662,879
21,662,879
1,230.2
3,023,451
(38.6
(3,023,261
(90.6
Balance, December 31, 2001
550,722,333
182,152,687
5,203.5
(327.1
(47.3
913.9
(21.5
(391.5
2,218,959
7.0
(2,218,959
(45.4
(20,036,204
20,036,204
1,082.9
3,096,696
(41.8
(3,096,696
(88.7
Balance, December 31, 2002
536,001,784
196,873,236
6,152.3
Consolidated Statements of Cash Flows
(Dollars in Millions)
Operating Activities
Adjustments to reconcile net income to netcash provided by operations:
Depreciation and amortization
296.5
336.2
337.8
Gain on sale of businesses and other investment activities
(5.2
(10.8
(125.6
Voluntary contributions to benefit plans
(110.0
(95.7
Cash effects of changes in:
Receivables
(18.0
19.4
(91.9
(2.4
(18.7
59.0
Accounts payable and other accruals
137.7
(52.5
97.8
Deferred and accrued income taxes
5.3
146.4
197.1
Other non-current assets and liabilities
19.0
33.0
(1.8
Net cash provided by operations
1,611.2
1,503.9
1,536.2
Investing Activities
Capital expenditures
(343.7
(340.2
(366.6
Payment for acquisitions, net of cash acquired
(10.2
(64.9
Sale of non-core product lines
12.5
102.5
Sale of marketable securities and investments
1.5
9.3
137.4
(17.0
Net cash used in investing activities
(357.2
(323.5
(208.6
Financing Activities
Principal payments on debt
(763.5
(595.9
(739.4
Proceeds from issuance of debt
964.5
887.9
925.4
Payments from (to) outside investors
89.7
(113.9
Dividends paid
(413.4
(396.7
(382.4
Purchase of common stock
(1,082.9
(1,230.2
(1,040.6
35.3
34.5
34.9
Net cash used in financing activities
(1,260.0
(1,210.7
(1,316.0
Effect of exchange rate changes on cash and cash equivalents
(3.6
(4.6
Net (decrease) increase in cash and cash equivalents
(4.8
(33.9
Cash and cash equivalents at beginning of year
206.6
199.6
Cash and cash equivalents at end of year
Supplemental Cash Flow Information
Income taxes paid
558.8
346.8
306.3
Interest paid
163.0
221.5
203.0
Principal payments on ESOP debt, guaranteed by the Company
17.8
12.9
8.8
The Company manufactures and markets a wide variety of products in the U.S. and around the world in two distinct business segments: Oral, Personal, Household Surface and Fabric Care; and Pet Nutrition. Oral, Personal, Household Surface and Fabric Care products include toothpaste, oral rinses and toothbrushes, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, shave products, laundry and dishwashing detergents, fabric conditioners, cleansers and cleaners, bleaches and other similar items. These products are sold primarily to wholesale and retail distributors worldwide. Pet Nutrition products include pet food products manufactured and marketed by Hills Pet Nutrition. The principal customers for Pet Nutrition products are veterinarians and specialty pet retailers. Principal global trademarks include Colgate, Palmolive, Kolynos, Sorriso, Mennen, Protex, Ajax, Soupline, Suavitel, Fab, Science Diet and Prescription Diet in addition to various regional trademarks.
The Companys principal classes of products accounted for the following percentages of worldwide sales for the past three years:
Oral Care
34
%
Personal Care
Household Surface Care
Fabric Care
Principles of Consolidation
The Consolidated Financial Statements include the accounts of Colgate-Palmolive Company and its majority-owned subsidiaries. Intercompany transactions and balances have been eliminated. The Companys investments in consumer products companies with interests ranging between 20% and 50% are accounted for using the equity method. As of December 31, 2002 and 2001, equity method investments were $12.5 and $14.5, respectively. Investments with less than a 20% interest are accounted for using the cost method. Unrelated third parties hold the remaining ownership interest in these investments. Net income (loss) from such investments is recorded in Other expense, net, in the Consolidated Statements of Income.
Use of Estimates
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to use judgment and make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent gains and losses at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. As such, the most significant uncertainty in the Companys assumptions and estimates involved in preparing the financial statements include pension and other retiree benefit cost assumptions, asset impairment, tax valuation allowances, and legal and other contingency reserves. Actual results could ultimately differ from those estimates.
Revenue Recognition
Sales are recorded at the time products are shipped to trade customers and when risk of ownership transfers. Net sales reflect units shipped at selling list prices reduced by sales returns and the cost of current and continuing promotional programs. Current promotional programs such as product listing allowances are recorded in the
Notes to Consolidated Financial Statements(continued)
period incurred. Continuing promotional programs are predominantly consumer coupons and volume-based sales incentive arrangements with trade customers. The redemption cost of consumer coupons is based on historical redemption experience and is recorded when coupons are distributed. Volume-based incentives offered to trade customers are based on the estimated cost of the program and are recorded as products are sold.
Shipping and Handling Costs
Shipping and handling costs are classified as selling, general and administrative expenses and were $647.8, $631.0 and $619.9 for the years ended December 31, 2002, 2001 and 2000, respectively.
Marketing Costs
The Company markets its products through advertising and other promotional activities. Advertising costs are included in selling, general and administrative expenses and are expensed as incurred. Promotional programs, such as consumer coupons, are recorded as a reduction of sales.
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.
Inventories are stated at the lower of cost or market. The cost of approximately 80% of inventories is determined using the first-in, first-out (FIFO) method. The cost of all other inventories, predominantly in the U.S. and Mexico, is determined using the last-in, first-out (LIFO) method.
Property, Plant and Equipment
Land, buildings, and machinery and equipment are stated at cost. Depreciation is provided, primarily using the straight-line method, over estimated useful lives, ranging from 3 to 40 years.
Goodwill and Other Intangibles
As described further below, the Company adopted Statement of Financial Accounting Standards (SFAS) No. 142 on January 1, 2002. In accordance with SFAS No. 142, goodwill and indefinite life intangible assets, such as the Companys global brands, are no longer amortized but subject to annual impairment tests. The required impairment tests were performed and did not result in an impairment charge. Prior to 2002, these assets were amortized on the straight-line method, generally over 40 years. Other intangible assets with finite lives, such as non-compete agreements, continue to be amortized over their useful lives, ranging from 5 to 40 years.
The provision for income taxes is determined using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized based upon the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect at the time such differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Provision is made currently for taxes payable on remittances of overseas earnings; no provision is made for taxes on overseas retained earnings that are deemed to be permanently reinvested.
30
Financial Instruments
Derivative instruments are recorded as assets and liabilities at estimated fair value based on available market information. The Companys derivative instruments that qualify for hedge accounting are primarily designated as either fair value hedges or cash flow hedges. For fair value hedges, changes in fair value of the derivative, as well as the offsetting changes in fair value of the hedged item, are recognized in earnings each period. For cash flow hedges, changes in fair value of the derivative are recorded in other comprehensive income and are recognized in earnings when the offsetting effect of the hedged item is also recognized in earnings.
The Company may also enter into certain foreign currency and interest rate derivative instruments that economically hedge certain of its risks but do not qualify for hedge accounting. Changes in fair value of these derivative instruments, based on quoted market prices, are recognized in earnings each period.
Stock-Based Compensation
Stock-based compensation plans, more fully described in Note 8, are accounted for under the provisions of Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations. The value of restricted stock awards, based on market prices, is amortized over the restriction period. No compensation expense has been recognized for stock option grants as all such grants had an exercise price not less than fair market value on the date of grant. The following illustrates the effect on net income and earnings per share if the Company had applied the fair value method of SFAS No. 123, Accounting for Stock-Based Compensation:
Year Ended December 31
Net income, as reported
Deduct: pro forma stock option compensation expense, net of tax
39.5
44.9
57.7
Pro forma net income
1,248.8
1,101.7
1,006.1
Earnings per share:
Basicas reported
Basicpro forma
2.26
1.94
1.71
Dilutedas reported
Dilutedpro forma
2.12
1.60
Pro forma stock option compensation expense above is the estimated fair value of options granted amortized over the vesting period. The weighted average estimated fair value of stock options granted in 2002, 2001 and 2000 was $9.50, $9.37 and $10.95, respectively. Fair value is estimated using the Black-Scholes option pricing model with the following assumptions: option term until exercise ranging from 2 to 8 years, volatility ranging from 21% to 41%, risk-free interest rate ranging from 1.7% to 6.2% and an expected dividend yield ranging from 2.0% to 2.5%. Options issued under the reload feature, as described in Note 8, are treated as newly issued options in the model.
Translation of Overseas Currencies
The assets and liabilities of foreign subsidiaries, other than those operating in highly inflationary environments, are translated into U.S. Dollars at year-end exchange rates, with resulting translation gains and losses accumulated in a separate component of shareholders equity. Income and expense items are translated into U.S. Dollars at average rates of exchange prevailing during the year.
For subsidiaries operating in highly inflationary environments, inventories, goodwill and property, plant and equipment are translated at the rate of exchange on the date the assets were acquired, while other assets and
31
liabilities are translated at year-end exchange rates. Translation adjustments for these operations are included in net income.
On January 1, 2002, the Company adopted the Financial Accounting Standards Boards (FASB) Emerging Issues Task Force (EITF) Issue No. 00-14, Accounting for Certain Sales Incentives, and Issue No. 00-25, Vendor Income Statement Characterization of Consideration Paid to a Reseller of the Vendors Products, that relate to the classification of various types of sales incentives and promotional expenses. The Consolidated Statements of Income for 2001 and 2000 have been revised to reflect the reclassification of certain sales incentives and promotional expenses from selling, general and administrative expenses to a reduction of net sales and cost of sales; however, the revisions had no impact on the Companys financial position, net income or earnings per share. These reclassifications reduced net sales by $343.5 and $353.5 and cost of sales by $2.0 and $8.5, for the years ended December 31, 2001 and 2000, respectively, with an offsetting reduction in each period in selling, general and administrative expenses.
On January 1, 2002, the Company adopted SFAS No. 142, Goodwill and Other Intangible Assets, which eliminates the amortization of goodwill and indefinite life intangible assets but requires annual impairment reviews. In accordance with SFAS No. 142, prior period amounts were not restated. (Refer to Note 5 for additional information on goodwill and other intangible assets.) The following table presents previously reported net income and earnings per share for the years ended December 31, 2001 and 2000, adjusted to exclude amortization expense, net of the related income tax effect for goodwill and other intangible assets that are no longer being amortized:
Net
Income
Basic
EPS
Diluted
Reported
Add: amortization adjustment, net of tax
43.8
.08
.07
47.8
Adjusted
1,190.4
2.10
1.96
1,111.6
1.77
On January 1, 2002, the Company adopted SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, which establishes criteria and methodologies for the measurement, recognition and classification of long-lived assets. The adoption of SFAS No. 144 did not have a material impact on the Companys Consolidated Financial Statements.
In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities, requiring companies to recognize liabilities and costs associated with exit or disposal activities initiated after December 31, 2002 when they are incurred, rather than when management commits to an exit or disposal plan. SFAS No. 146 also requires that such liabilities be measured at fair value. SFAS No. 146 had no impact on the Companys Consolidated Financial Statements but may affect the measurement and recognition of any future restructuring activities.
In November 2002, the FASB issued Interpretation No. 45, Guarantors Accounting and Disclosure of Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, which elaborates on the existing disclosure requirements for guarantees and provides clarification on when a company must measure and recognize a liability related to guarantees issued. The disclosure requirements of Interpretation No. 45 are effective for the Companys Consolidated Financial Statements for the year ended December 31, 2002. The
32
measurement and recognition provisions are to be applied on a prospective basis for guarantees issued or modified after December 31, 2002. The adoption of Interpretation No. 45 did not require additional disclosures and is not expected to impact the Companys Consolidated Financial Statements as the Company does not issue guarantees related to third-party indebtedness or performance.
In January 2003, the FASB issued Interpretation No. 46, Consolidation of Variable Interest Entities, which provides new guidance with respect to the consolidation of all unconsolidated entities, including special purpose entities. The adoption of Interpretation No. 46 in 2003 is not expected to impact the Companys Consolidated Financial Statements as the Company does not have investments in any unconsolidated special purpose or variable interest entities.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation.
During 2002 and 2001, the Company did not make any significant acquisitions. In 2000, the Company made several acquisitions totaling $64.9. Individually, none of these acquisitions were significant to the Company. The acquisitions were accounted for as purchases, and accordingly, the purchase prices were allocated to the net tangible and intangible assets acquired based on estimated fair values at the dates the acquisitions were consummated.
The Company did not have any significant divestitures in 2002. The aggregate sale price of all 2001 and 2000 divestitures was $12.5 and $102.5, respectively. These divestitures included certain Central American detergent product lines in 2001 and the Mexico Viva detergent brand in 2000.
In December 2000, the Company recorded a charge of $63.9 ($42.5 aftertax) associated with the realignment of three manufacturing locations in Latin America and the exiting of its business in Nigeria. The charge, recorded in Other expense, net, included $14.2 for termination costs and $49.7 for exiting of manufacturing operations. The restructuring was completed in 2001.
The net carrying value of goodwill as of December 31, 2002 and 2001 by operating segment is as follows:
250.1
249.6
433.6
568.7
379.9
350.2
104.2
100.7
1,167.8
1,269.2
15.0
33
The change in the net carrying amount of goodwill during the year ended December 31, 2002 is due to the impact of foreign currency translation adjustments. The net carrying value of indefinite life intangible assets as of December 31, 2002 was $357.5 and relates to certain of the Companys global brands.
Finite life intangible assets as of December 31, 2002, subject to amortization, are comprised of the following:
Gross
Carrying
Accumulated
Amortization
Trademarks
367.1
(120.1
247.0
Other intangible assets
7.8
(3.8
4.0
374.9
(123.9
251.0
Amortization expense of the above trademarks and other intangible assets was $12.5 for the year ended December 31, 2002. Annual estimated amortization expense for each of the next five years is expected to approximate $12.
Long-term debt consists of the following at December 31:
Weighted Average
Interest Rate
Maturities
Notes
4.8
20032078
2,244.7
1,724.7
Commercial paper
1.7
391.4
605.8
ESOP notes, guaranteed by the Company
8.7
20032009
327.3
345.2
Payable to banks
4.4
20032007
495.7
451.5
10.3
3,509.3
3,137.5
Less: current portion of long-term debt
Commercial paper and certain current maturities of notes payable totaling $815.5 are classified as long-term debt as the Company has the intent and ability to refinance such obligations on a long-term basis. Scheduled maturities of long-term debt and capitalized leases outstanding as of December 31, 2002, excluding commercial paper and certain current maturities of notes payable reclassified, are as follows: 2003$298.5; 2004$313.3; 2005$405.8; 2006$271.9; 2007$253.5 and $1,150.8 thereafter. The Company has entered into interest rate swap agreements and foreign exchange contracts related to certain of these debt instruments (see Note 7).
At December 31, 2002, the Company had unused credit facilities amounting to $2,082.6. Commitment fees related to credit facilities are not material. The weighted average interest rate on short-term borrowings, included in Notes and loans payable in the Consolidated Balance Sheets, as of December 31, 2002 and 2001, was 6.4% and 5.6%, respectively.
The Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments. Some judgment is required in interpreting market data to develop the estimates of fair value, and accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates.
Derivative Instruments
Following are the notional amounts and net recorded fair values of the Companys derivative instruments:
Notional Amount
Fair Value
Interest rate swap contracts
1,103
46.6
788.8
(13.7
Foreign currency contracts
1,334
4.6
591.2
11.9
The Company utilizes interest rate swap contracts to manage its targeted mix of fixed and floating rate debt. Forward and swap contracts are utilized to hedge a portion of the Companys foreign currency purchases and assets and liabilities created in the normal course of business. Forward contracts used in hedging forecasted foreign currency purchases have durations no greater than 18 months. It is the Companys policy to enter into derivative instruments with terms that match the underlying exposure being hedged. As such, the Companys derivative instruments are considered highly effective and the net gain or loss from hedge ineffectiveness was not material.
The cumulative gains (losses) related to those foreign currency contracts and interest rate swap contracts designated as cash flow hedges expected to be recognized in earnings over the next 12 months, when the offsetting effects of the hedged item are also recorded in earnings, are $(3.2) and $(6.8), respectively.
Other Financial Instruments
The carrying amount of cash and cash equivalents, marketable securities, long-term investments and short-term debt approximated fair value as of December 31, 2002 and 2001. The estimated fair value of the Companys long-term debt, including current portion, as of December 31, 2002 and 2001, was $3,779.7 and $3,312.5, respectively, and the related carrying value was $3,509.3 and $3,137.5, respectively.
Credit Risk
Preferred Stock
Preferred Stock consists of 250,000 authorized shares without par value. It is issuable in series, of which one series of 125,000 shares, designated $4.25 Preferred Stock, with a stated and redeemable value of
35
$100 per share, has been issued. The $4.25 Preferred Stock is redeemable only at the option of the Company. As of December 31, 2002 and 2001, 103,160 shares of $4.25 Preferred Stock were outstanding.
Preference Stock
In 1988, the Company authorized the issuance of 50,000,000 shares of Series B Convertible Preference Stock (the Preference Stock), without par value. The Preference Stock is convertible into eight shares of common stock and ranks junior to all series of the Preferred Stock. As of December 31, 2002 and 2001, 4,777,538 and 5,059,086 shares of the Preference Stock, respectively, were outstanding and issued to the Companys Employee Stock Ownership Plan.
Shareholder Rights Plan
Under the Companys Shareholder Rights Plan, each share of the Companys common stock carries with it one Preference Share Purchase Right (Rights). The Rights do not have voting power or pay dividends and become exercisable upon the acquisition or tender of 15% or more of the Companys common stock. When exercisable, each Right entitles a holder to buy one two-hundredth of a share of a new series of preference stock at an exercise price of $220.00, subject to adjustment.
If 15% or more of the Companys common stock is acquired, each Right will entitle its holder (other than the acquirer) to purchase, at the Rights then current exercise price, a number of shares of the Companys common stock having a market value of twice the Rights exercise price.
In addition, if 15% to 50% of the Companys common stock is acquired, the Board of Directors may exchange part or all of the Rights (other than Rights held by the acquirer) for shares of the Companys common stock on a one-for-one basis.
If the Company is acquired in a merger or other business combination, each Right will entitle a holder to buy, at the Rights then current exercise price, a number of the acquiring companys common shares having a market value of twice such price.
The Board of Directors may amend the Rights or redeem the Rights for $.01 at any time before the acquisition of 15% or more of the Companys common stock and is also authorized to reduce the 15% threshold to not less than 10%. Unless redeemed earlier, the Rights will expire on October 31, 2008.
Stock Repurchases
The Company purchases shares under a stock repurchase program authorized by the Board of Directors. Stock purchases in 2002 of $1,082.9 included $388.9 for the termination of all forward purchase agreements in which the Company repurchased all of the shares held by the counterparty under the agreement.
Incentive Stock Plan
The Company has a plan that provides for grants of restricted stock awards for officers and other executives of the Company and its major subsidiaries. A committee of independent members of the Board of Directors administers the plan. The awarded shares are made in common stock and vest at the end of the restriction period, generally between three and five years. During 2002 and 2001, 549,000 and 511,000 shares, respectively, were
36
awarded to employees in accordance with the provisions of the plan. The Company recognized compensation expense for the plan of $29.5, $26.6 and $23.6 for the years ended December 31, 2002, 2001 and 2000, respectively. As of December 31, 2002, there were 2,252,000 restricted shares awarded but not vested.
Stock Option Plans
The Companys Stock Option Plans (Plans) provide for the issuance of non-qualified stock options to officers and key employees. Options are granted at prices not less than the fair market value on the date of grant with a term of up to ten years and generally vest over three to five years. As of December 31, 2002, 15,936,000 shares of common stock were available for future grants.
The Plans contain a reload feature that provides for the grant of new options when previously owned shares of Company stock are used to exercise existing options. The number of new options granted under this feature is equal to the number of shares of previously owned Company stock used to exercise the original options and to pay the related required U.S. income tax. The new options are granted at a price equal to the fair market value on the date of the new grant and have shorter expected lives as they have the same expiration date as the original options exercised and vest over six months.
Stock option plan activity is summarized below:
Shares (in thousands)
Weighted Average Exercise Price
Options outstanding, January 1
40,933
44
39,143
41
39,196
Granted
6,229
7,842
57
9,762
Exercised
(3,049
(5,565
37
(9,361
Canceled or expired
(1,059
(487
(454
40
Options outstanding, December 31
43,054
46
Options exercisable, December 31
30,555
43
26,549
39
24,840
The following table summarizes information relating to currently outstanding and exercisable options as of December 31, 2002:
Range of Exercise Prices
Weighted Average Remaining Contractural Life (in years)
Options Outstanding (in thousands)
Options Exercisable (in thousands)
$12.95$19.42
1
3,173
$19.43$32.37
5,393
5,286
$32.38$45.32
4,624
4,482
$45.33$51.80
4,962
3,107
$51.81$58.27
21,884
11,787
$58.28$64.75
3,018
60
2,720
In 1989, the Company expanded its Employee Stock Ownership Plan (ESOP) through the introduction of a leveraged ESOP that funds certain benefits for employees who have met eligibility requirements. The ESOP issued $410.0 of long-term notes due through 2009 bearing an average interest rate of 8.7%. The long-term notes, which are guaranteed by the Company, are reflected in the accompanying Consolidated Balance Sheets. The ESOP used the proceeds of the notes to purchase 6.3 million shares of Series B Convertible Preference Stock (the Preference Stock) from the Company. The Preference Stock has a minimum redemption price of $65 per share and pays semiannual dividends equal to the higher of $2.44 or the current dividend paid on eight common shares for the comparable six-month period. During 2000, the ESOP entered into a loan agreement with the Company under which the benefits of the ESOP may be extended through 2035.
Dividends on the Preference Stock, as well as on the common shares also held by the ESOP, are paid to the ESOP trust and, together with cash contributions and advances from the Company, are used by the ESOP to repay principal and interest on the outstanding notes. Preference Stock is released for allocation to participants based upon the ratio of the current years debt service to the sum of total principal and interest payments over the life of the loan. As of December 31, 2002, 1,635,000 shares were allocated to participant accounts and 3,143,000 shares were available for future allocation. Each share may be converted by the ESOP Trustee into eight common shares but allocated Preference Stock generally converts only after the employee ceases to work for the Company.
Dividends on the Preference Stock are deductible for income tax purposes and, accordingly, are reflected net of their tax benefit in the Consolidated Statements of Retained Earnings, Comprehensive Income and Changes in Capital Accounts.
Annual expense related to the leveraged ESOP, determined as interest incurred on the original notes, plus the higher of either principal payments or the historical cost of Preference Stock allocated, less dividends received on the shares held by the ESOP and advances from the Company, was $7.0 in 2002, $0 in 2001 and $3.4 in 2000. Unearned compensation, which is shown as a reduction in shareholders equity, represents the amount of ESOP debt outstanding reduced by the difference between the cumulative cost of Preference Stock allocated and the cumulative principal payments.
Interest incurred on the ESOPs notes was $29.0 in 2002, $30.4 in 2001 and $31.4 in 2000. The Company paid dividends on the shares held by the ESOP of $29.6 in 2002, $29.4 in 2001 and $28.6 in 2000. Company contributions to the ESOP were $15.9 in 2002, $0 in 2001 and $4.8 in 2000.
Retirement Plans
The Company, its U.S. subsidiaries and some of its overseas subsidiaries maintain defined benefit retirement plans covering substantially all of their employees. Benefits are based primarily on years of service and employees career earnings. In the Companys principal U.S. plans, funds are contributed to the trusts in accordance with regulatory limits to provide for current service and for any unfunded projected benefit obligation over a reasonable period. Assets of the plans consist principally of common stocks, guaranteed investment contracts with insurance companies, investments in real estate funds, and U.S. Government and corporate obligations. Domestic plan assets also include investments in the Companys common stock representing 9% and 10% of plan assets at December 31, 2002 and 2001, respectively.
38
Other Retiree Benefits
The Company and certain of its subsidiaries provide health care and life insurance benefits for retired employees to the extent not provided by government-sponsored plans. The Company utilizes a portion of its leveraged ESOP, in the form of future retiree contributions, to reduce its obligation to provide these postretirement benefits and to offset its current service cost. Postretirement benefits otherwise are not currently funded.
Summarized information for the Companys defined benefit retirement plans and postretirement plans are as follows:
Pension Benefits
OtherRetiree Benefits
International
Change in Benefit Obligation
Benefit obligation at beginning of year
1,028.5
938.3
357.1
345.0
183.6
164.2
Service cost
31.8
12.4
11.1
(4.0
Interest cost
72.6
22.6
21.5
17.5
16.6
Participants contributions
2.9
2.7
2.2
2.1
Acquisitions/plan amendments
1.0
.2
1.9
Actuarial loss
70.3
8.1
.5
23.9
Foreign exchange impact
34.6
(14.9
2.6
(3.7
Benefit payments
(85.6
(86.1
(24.2
(19.9
(14.0
(12.8
Benefit obligation at end of year
1,116.3
413.0
185.8
Change in Plan Assets
Fair value of plan assets at beginning of year
900.1
932.7
217.1
243.7
Actual return on plan assets
(57.2
(54.2
(11.5
(8.2
Company contributions
145.5
105.0
12.6
14.0
12.8
15.6
(13.2
Fair value of plan assets at end of year
905.7
217.0
Funded Status
Funded status at end of year
(210.6
(128.4
(196.0
(140.0
(185.8
(183.6
Unrecognized net actuarial loss
393.5
200.8
95.3
46.4
14.7
13.5
Unrecognized transition/prior service costs
18.5
20.7
6.4
7.6
(4.3
(5.4
Net amount recognized
201.4
93.1
(94.3
(86.0
(175.4
(175.5
Amounts Recognized in Balance Sheet
Prepaid benefit cost
311.6
198.4
16.0
Accrued benefit liability
(148.8
(105.3
(159.4
(120.7
38.6
49.1
12.1
Weighted Average Assumptions
Discount rate
6.75
7.25
6.51
6.69
Long-term rate of return on plan assets
8.00
9.00
8.48
8.86
Long-term rate of compensation increase
4.25
4.75
3.84
3.96
ESOP growth rate
10.00
The United States pension benefits include funded qualified plans covering most domestic employees and certain unfunded non-qualified plans. As of December 31, 2002 and 2001, the United States qualified pension plans had benefit obligations of $939.8 and $892.2, and plan assets of $902.4 and $896.8, respectively.
Components of Net Periodic Benefit Costs
27.8
5.0
3.7
68.2
22.0
Annual ESOP allocation
(9.0
(8.6
(9.2
Expected return on plan assets
(82.5
(86.6
(92.9
(16.9
(19.1
Amortization of transition/prior service costs
3.1
7.1
7.2
(.1
.1
(1.0
Amortization of actuarial loss (gain)
9.5
.8
(6.6
2.0
.7
.3
Net periodic benefit cost
37.2
24.6
20.0
12.7
The accumulated benefit obligation and fair value of plan assets for the pension plans with accumulated benefit obligations in excess of plan assets were $448.5 and $148.2, respectively, as of December 31, 2002, and $287.2 and $69.5, respectively, as of December 31, 2001. These amounts represent non-qualified domestic plans and plans at foreign locations that are primarily unfunded; as such, book reserves equal to the unfunded amounts have been recorded.
The projected benefit obligation and fair value of plan assets for the pension plans with projected benefit obligations in excess of plan assets were $1,517.6 and $1,108.5, respectively, as of December 31, 2002, and $472.6 and $199.5, respectively, as of December 31, 2001.
The assumed medical cost trend rate used in measuring the postretirement benefit obligation was 9% for 2003, 8% for 2004, 7% for 2005, 6% for 2006 and 5% for years thereafter. Changes in this rate can have a significant effect on amounts reported. The effect of a 1% increase in the assumed medical cost trend rate would increase the accumulated postretirement benefit obligation by approximately $17.0 and increase the annual expense by approximately $2.0. The effect of a 1% decrease in the assumed medical cost trend rate would decrease the accumulated postretirement benefit obligation by approximately $13.0 and decrease the annual expense by approximately $1.5.
The provision for income taxes consists of the following for the three years ended December 31:
176.5
153.5
150.9
405.5
368.6
352.5
The components of income before income taxes are as follows for the three years ended December 31:
548.4
474.5
483.3
1,321.9
1,194.2
1,083.9
The difference between the statutory U.S. federal income tax rate and the Companys global effective tax rate as reflected in the Consolidated Statements of Income is as follows:
Percentage of Income Before Tax
Tax at U.S. statutory rate
35.0
State income taxes, net of federal benefit
.6
.4
Earnings taxed at other than U.S. statutory rate
(3.2
(3.0
(1.7
Other, net
(1.3
(1.6
Effective tax rate
31.1
31.3
32.1
In addition, net tax benefits of $51.1 in 2002, $54.4 in 2001 and $91.6 in 2000 were recorded directly through equity which included tax benefits related to certain employee benefit plans and exchange losses on U.S. Dollar-denominated investments in foreign subsidiaries.
Temporary differences between accounting for financial statement purposes and accounting for tax purposes result in taxes currently payable being lower than the total provision for income taxes as follows:
Property, plant and equipment
(12.4
(12.1
Pension and other postretirement benefits
(19.6
(29.0
Alternative Minimum Tax credit utilization
(89.1
(18.5
(.7
44.1
(50.5
(56.4
The components of deferred tax assets (liabilities) are as follows at December 31:
Deferred TaxesCurrent:
Accrued liabilities
75.3
65.3
35.1
43.5
Total deferred taxes, current
110.4
108.8
Deferred TaxesLong-term:
Intangible assets
(268.0
(266.7
(278.5
(269.5
Tax loss and tax credit carryforwards
146.1
100.0
47.1
40.0
Valuation allowance
(135.5
(84.4
Total deferred taxes, long-term
(488.8
(480.6
Net deferred taxes
(378.4
(371.8
The major component of the 2002 and 2001 valuation allowance relates to tax benefits in certain jurisdictions arising from net operating losses expiring through 2007, not expected to be realized.
Applicable U.S. income and foreign withholding taxes have not been provided on approximately $954.5 of undistributed earnings of foreign subsidiaries at December 31, 2002. These earnings have been and are currently considered to be permanently invested and are currently not subject to such taxes. Determining the tax liability that would arise if these earnings were remitted is not practicable.
For the Year Ended 2002
For the Year Ended 2001
For the Year Ended 2000
Shares (millions)
Per
Share
Preferred dividends
(21.9
(21.7
(20.7
Basic EPS
1,266.4
542.7
557.8
1,043.1
574.9
Stock options and restricted stock
7.3
9.8
Convertible preference stock
39.1
21.3
41.1
20.3
42.6
Diluted EPS
1,287.9
589.1
1,146.2
607.7
1,063.4
627.3
In determining the dilutive effect of the stock options, the number of shares resulting from the assumed exercise of the options is appropriately reduced by the number of shares that could have been purchased by the Company with the proceeds from the exercise of such options.
Minimum rental commitments under noncancellable operating leases, primarily for office and warehouse facilities, are $72.3 in 2003, $62.7 in 2004, $55.8 in 2005, $49.7 in 2006, $48.8 in 2007 and $98.3 thereafter. Rental expense amounted to $97.8 in 2002, $96.9 in 2001 and $90.6 in 2000. Contingent rentals, sublease income and capital leases, which are included in fixed assets, are not significant. The Company has various contractual commitments to purchase raw materials, products and services totaling $108.2 that expire through 2005.
The Company is party to various superfund and other environmental matters in connection with prior acquisitions and has been named as a potentially responsible party for the cleanup, restoration and post-closure monitoring of several sites. The Company has been apportioned a share of the liabilities associated with the cleanup activities, and substantially all of these liabilities have been acknowledged in writing as being covered by investment-grade insurance carriers that are presently making all their required payments directly to the cleanup efforts and are expected to do so in the future. Management proactively reviews and monitors its exposure to, and the impact of, environmental matters. While it is possible that the nonperformance of other potentially responsible parties could affect the cash flows and results of operations in any particular quarter or year, it is the opinion of management that the ultimate disposition of these matters, to the extent not previously provided for, will not have a material impact on the financial position, results of operations or ongoing cash flows of the Company.
In 1995, the Company acquired the Kolynos oral care business from Wyeth (formerly American Home Products) (the Seller), as described in the Companys Form 8-K dated January 10, 1995. On September 8, 1998, the Companys Brazilian subsidiary received notice of an administrative proceeding from the Central Bank of Brazil primarily taking issue with certain foreign exchange filings made with the Central Bank in connection with the financing of this strategic transaction, but in no way challenging or seeking to unwind the acquisition.
42
The Central Bank of Brazil in January 2001 notified the Company of its decision in this administrative proceeding to impose a fine, which, at the current exchange rate, approximates $75. The Company has appealed the decision to the Brazilian Monetary System Appeals Council (the Council), thereby suspending the fine pending the decision of the Council. If the fine is affirmed, interest and penalties may also be assessed. Further appeals are available within the Brazilian federal courts. Management believes, based on the opinion of its Brazilian legal counsel and other experts, that the filings challenged by the Central Bank fully complied with Brazilian law and that the Company will prevail on appeal. The Company intends to challenge this fine vigorously. In addition, Brazilian prosecutors are reviewing the foregoing transactions as part of an overall examination of all international transfers of Reais through non-resident current accounts during the 1992 to 1998 time frame. The Company understands that this examination involves hundreds and possibly thousands of other individuals and companies. In 2002, the Brazilian Federal Public Attorney filed a civil action against the federal government of Brazil, Laboratorios Wyeth-Whitehall Ltda., the Brazilian subsidiary of the Seller, and the Company, as represented by its Brazilian subsidiary, seeking to annul an April 2000 decision by the Brazilian Board of Tax Appeals that found in favor of the Sellers subsidiary on the issue of whether it had incurred taxable capital gains as a result of the divestiture of Kolynos. The action seeks to make the Companys Brazilian subsidiary jointly and severally liable for any tax due from the Sellers subsidiary. Management believes, based on the opinion of its Brazilian legal counsel, that the Company will ultimately prevail in this action. The Company intends to challenge this action vigorously.
In addition, the Brazilian internal revenue authority has disallowed interest deductions and foreign exchange losses taken by the Companys Brazilian subsidiary in connection with the financing of the Kolynos acquisition, imposing a tax assessment that has been determined, at the current exchange rate, to approximate $30. The Company has filed an administrative appeal with the Brazilian internal revenue authority, and further appeals are available within the Brazilian federal courts. Management believes, based on the opinion of its Brazilian legal counsel and other experts, that the disallowance is without merit and that the Company will prevail on appeal. The Company intends to challenge this assessment vigorously.
While it is possible that the Companys cash flows and results of operations in a particular quarter or year could be affected by the one-time impacts of the resolution of such contingencies, it is the opinion of management that the ultimate disposition of these matters, to the extent not previously provided for, will not have a material impact on the Companys financial position, results of operations or ongoing cash flows.
The Company operates in two product segments: Oral, Personal, Household Surface and Fabric Care; and Pet Nutrition. The operations of the Oral, Personal, Household Surface and Fabric Care segment are managed geographically in four reportable operating segments: North America, Latin America, Europe and Asia/Africa. Management evaluates segment performance based on several factors, including operating profit. The Company uses operating profit as a measure of the basic health of the operating segments because it excludes the impact of corporate-driven decisions related to interest expense and income taxes.
The accounting policies of the operating segments are generally the same as those described in Note 2. Intercompany sales have been eliminated. Amounts for certain businesses in the Caribbean, which were previously reported in Latin America, have been reclassified to North America to conform with current year presentation and change in management responsibilities. Corporate operations include research and development costs, unallocated overhead costs, and gains and losses on sales of non-strategic brands and assets. Corporate
assets primarily include benefit plan assets. Segment information regarding net sales, operating profit, identifiable assets, capital expenditures, and depreciation and amortization is detailed below:
Total Net Sales
Total Operating Profit
Identifiable Assets
2,064.3
2,108.6
2,172.6
1,661.4
1,934.9
2,041.5
1,371.9
1,263.6
1,369.4
1,005.3
942.7
1,013.0
6,102.9
6,249.8
6,596.5
552.5
497.6
478.5
431.8
237.4
177.3
Total Identifiable Assets(1)
7,252.3
Capital Expenditures
65.0
70.5
93.4
106.4
115.6
119.7
37.7
33.3
41.7
54.6
36.5
45.8
263.7
255.9
300.6
39.4
37.0
29.2
40.6
47.3
36.8
Total Capital Expenditures
343.7
340.2
366.6
Depreciation and Amortization
82.1
102.8
101.2
53.8
69.3
73.0
57.3
64.9
67.8
46.3
47.0
239.5
284.8
289.0
28.7
28.1
30.6
28.3
23.3
18.2
Total Depreciation and Amortization
Minority interest
41.3
40.1
32.6
Amortization of intangible assets
68.0
72.1
Loss (gain) on equity investments
(.2
(2.2
(31.4
(13.4
(50.2
Interest incurred
158.2
192.4
203.5
Interest capitalized
(7.4
(14.4
Interest income
(8.0
(11.9
(26.4
Research and development
196.6
184.9
176.1
Media advertising(1)
486.6
509.0
550.9
45
Raw materials and supplies
176.6
188.0
Work-in-process
30.1
27.9
Finished goods
465.0
461.1
Inventories valued under LIFO amounted to $155.8 and $143.1 at December 31, 2002 and 2001, respectively. The excess of current cost over LIFO cost at the end of each year was $44.1 and $30.5, respectively. The liquidations of LIFO inventory quantities had no effect on income in 2002, 2001 and 2000.
Property, Plant and Equipment, Net
Land
132.7
128.8
Buildings
771.8
726.7
Machinery and equipment
3,752.4
3,553.4
4,656.9
4,408.9
Accumulated depreciation
(2,165.6
(1,895.4
Other Accruals
Accrued advertising
315.2
261.8
Accrued payroll and employee benefits
231.4
254.9
Accrued interest
19.1
Accrued taxes other than income taxes
48.6
264.6
234.1
Other Liabilities
209.1
204.1
Pension and other benefits
483.6
401.5
116.7
Accumulated Other Comprehensive Income
Accumulated other comprehensive income is comprised of cumulative foreign currency translation gains and losses, minimum pension liability adjustments, unrealized gains and losses from derivative instruments designated as cash flow hedges, and unrealized gains and losses from available-for-sale securities. As of December 31, 2002 and 2001, accumulated other comprehensive income primarily consisted of cumulative foreign currency translation adjustments.
The 2002 and 2001 cumulative translation adjustments resulted primarily from devaluation of the Brazilian Real of $175.9 and $105.0, and the Argentine Peso of $28.5 and $66.8, in each year, respectively. In 2000, the cumulative translation adjustments related primarily to the devaluation of the Brazilian Real of $45.1. These adjustments represented write-downs of foreign currency-denominated assets (primarily goodwill and property, plant and equipment) that will result in lower depreciation expense in future periods.
First
Quarter
Second
Third
Fourth
2,195.2
2,297.0
2,381.7
2,420.4
1,202.8
1,244.0
1,302.6
1,320.7
289.7
327.0
330.7
340.9
Earnings per common share:
.52
.59
.60
.62
.49
.55
.57
2,212.2
2,238.7
2,304.9
2,328.5
1,180.4
1,188.2
1,232.4
1,248.4
267.9
287.2
296.2
295.3
.47
.50
.53
.44
47
SCHEDULE IIVALUATION AND QUALIFYING ACCOUNTS
For the Year Ended December 31, 2002
Column A
Column B
Column C
Column D
Column E
Additions
Description
Balance at Beginning of Period
Charged to
Costs and
Expenses
Deductions
Balance at End
of Period
Allowance for doubtful accounts and estimated returns
45.6
8.4
45.9
Accumulated amortization of goodwill and other intangibles
719.0
731.5
Valuation allowance for deferred tax assets
84.4
$27.1(2)
24.0
(2)(3)
135.5
For the Year Ended December 31, 2001
39.8
11.7
5.9
651.0
74.7
27.0
(2)
17.3
For the Year Ended December 31, 2000
7.7
578.9
137.0
62.3
Report of Independent Accountants
To the Board of Directors and Shareholders of
Colgate-Palmolive Company:
In our opinion, the accompanying consolidated balance sheet as of December 31, 2002 and the related consolidated statements of income, retained earnings, comprehensive income and changes in capital accounts and cash flows for the year then ended present fairly, in all material respects, the financial position of Colgate-Palmolive Company and its subsidiaries (the Company) at December 31, 2002, and the results of their operations and their cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America. In addition, in our opinion, the accompanying financial statement schedule presents fairly, in all material respects, the information set forth therein for the year ended December 31, 2002 when read in conjunction with the related consolidated financial statements. These financial statements and financial statement schedule are the responsibility of the Companys management; our responsibility is to express an opinion on these financial statements and financial statement schedule based on our audit. We conducted our audit of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion. The financial statements of the Company as of December 31, 2001 and for each of the two years in the period ended December 31, 2001 (the Prior Year Financial Statements) before the adjustments disclosed in the Summary of Significant Accounting Policies note (Note 2), and the financial statement schedules for each of the two years in the period ended December 31, 2001 were audited by other independent accountants who have ceased operations. Those independent accountants expressed an unqualified opinion on those financial statements and financial statement schedules in their report dated February 4, 2002.
As disclosed in Note 2, the Company changed the manner in which it accounts for goodwill and other intangible assets upon adoption of the accounting guidance of Statement of Financial Accounting Standards No. 142 (SFAS 142) on January 1, 2002. In addition, as disclosed in Note 2, effective January 1, 2002, the Company changed the manner in which it recognizes, measures and displays certain sales incentives upon the adoption of the accounting guidance of Emerging Issues Task Force Issues 00-14 and 00-25 (EITF 00-14 and 00-25).
As discussed above, the Prior Year Financial Statements were audited by other independent accountants who have ceased operations. As disclosed in Note 2, such financial statements have been revised to include the transitional disclosures required by SFAS 142 and to reflect the adoption of EITF 00-14 and 00-25. We have audited the transitional disclosures contained in Note 2, and the adjustments applied to revise the Prior Year Financial Statements. In our opinion, these transitional disclosures and adjustments are appropriate and have been properly applied. However, we were not engaged to audit, review, or apply any procedures to the Prior Year Financial Statements other than with respect to such transitional disclosures and adjustments and, accordingly, we do not express an opinion or any other form of assurance on the Prior Year Financial Statements taken as a whole.
/s/ PRICEWATERHOUSECOOPERS LLP
New York, New York
February 3, 2003
The following report is a copy of a report previously issued by Arthur Andersen LLP that has not been reissued. The Arthur Andersen LLP report does not extend to the revision of the 2001 and 2000 Consolidated Statements of Income related to the change in accounting for sales incentives or the transitional disclosures related to the change in accounting for goodwill and intangible assets presented in Note 2 to the Consolidated Financial Statements. These revisions and transitional disclosures were audited by PricewaterhouseCoopers LLP as stated in their report appearing herein.
Report of Independent Public Accountants
We have audited the accompanying consolidated balance sheets of Colgate-Palmolive Company (a Delaware corporation) and subsidiaries as of December 31, 2001 and 2000, and the related consolidated statements of income, retained earnings, comprehensive income and changes in capital accounts, and cash flows for each of the three years in the period ended December 31, 2001. These financial statements and the schedules referred to below are the responsibility of the Companys management. Our responsibility is to express an opinion on these financial statements and schedules based on our audits.
We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Colgate-Palmolive Company and subsidiaries as of December 31, 2001 and 2000, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2001 in conformity with accounting principles generally accepted in the United States.
Our audit was made for the purpose of forming an opinion on the basic financial statements taken as a whole. The schedules listed in the index to financial statements are presented for purposes of complying with the Securities and Exchange Commissions rules and are not part of the basic financial statements. These schedules have been subjected to the auditing procedures applied in the audit of the basic financial statements and, in our opinion, fairly state in all material respects the financial data required to be set forth therein in relation to the basic financial statements taken as a whole.
/s/ ARTHUR ANDERSEN LLP
February 4, 2002
The Companys common stock and $4.25 Preferred Stock are listed on the New York Stock Exchange. The trading symbol for the common stock is CL. Dividends on the common stock have been paid every year since 1895 and the amount of dividends paid per common share has increased for 40 consecutive years.
Market Price
Common Stock
$4.25 Preferred Stock
Quarter Ended
High
Low
March 31
57.75
54.10
62.50
51.00
90.50
86.00
89.00
86.85
June 30
58.73
47.95
61.00
51.26
90.00
86.50
89.75
85.93
September 30
56.14
44.36
60.25
52.64
87.00
88.00
85.50
December 31
57.91
51.04
59.41
56.15
97.00
88.50
85.00
Closing Price
$52.43
$57.75
$95.25
$87.50
Dividends Paid Per Share
.1800
.1575
1.0625
.72
.675
Historical Financial Summary(1)
1999
1997
1995
1994
Continuing Operations
Net sales(2)
8,801.5
8,660.8
8,786.8
8,493.1
8,201.5
7,444.5
7,009.3
Results of operations:
937.3
848.6
740.4
635.0
172.0
(3)
580.2
(4)
189.9
(5)
Per share, basic
1.57
1.40
1.22
1.05
.26
.96
.27
Per share, diluted
1.47
1.30
1.13
.98
.25
.89
Depreciation and amortization expense
330.3
319.9
316.3
300.3
235.1
209.6
Financial Position
Current ratio
1.1
1.3
1.4
2,528.3
2,551.1
2,589.2
2,441.0
2,428.9
2,155.2
1,988.1
1,766.3
372.8
389.6
459.0
400.8
364.3
7,423.1
7,685.2
7,538.7
7,901.5
7,642.3
6,142.4
5,761.2
2,536.9
2,243.3
2,300.6
2,340.3
2,786.8
2,992.0
1,751.5
1,532.4
Shareholders equity
1,468.1
1,833.7
2,085.6
2,178.6
2,034.1
1,679.8
1,822.9
1,875.0
Share and Other
Book value per common share
.69
1.54
2.57
3.14
3.53
3.65
3.42
2.84
3.12
3.10
Cash dividends declared and paid per common share
.63
.39
.34
Closing price
52.43
64.55
65.00
46.44
36.75
23.06
17.56
15.84
15.59
Number of common shares outstanding (in millions)
536.0
550.7
566.7
585.4
590.8
588.6
583.4
577.6
597.0
Number of shareholders of record:
$4.25 Preferred
215
224
247
275
296
320
350
380
400
450
Common
38,800
40,900
42,300
44,600
45,800
46,800
45,500
46,600
44,100
40,300
Average number of employees
37,700
38,500
38,300
37,200
37,800
37,900
38,400
32,800
28,000
EXHIBITS TO FORM 10-K
YEAR ENDED DECEMBER 31, 2002
Commission File No. 1-644
Exhibit No.
3-A
Restated Certificate of Incorporation, as amended. (Registrant hereby incorporates by reference Exhibit 1 to its Form 8-K dated October 17, 1991, File No. 1-644-2.)
3-B
By-laws. (Registrant hereby incorporates by reference Exhibit 3-B to its Annual Report on Form 10-K for the year ended December 31, 2000, File No. 1-644.)
4-A
a)
Rights Agreement dated as of October 23, 1998 between registrant and First Chicago Trust Company of New York. (Registrant hereby incorporates by reference Exhibit 1 to its Form 8-A dated October 23, 1998, File No. 1-644-2.)
b)
Amendment, dated as of March 14, 2002, to the Rights Agreement between Equiserve (as successor to First Chicago Trust Company of New York) and Colgate-Palmolive Company, dated October 23, 1998. (Registrant hereby incorporates by reference Exhibit 4-A to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2002, File No. 1-644.)
4-B
Other instruments defining the rights of security holders, including indentures.*
Colgate-Palmolive Company Employee Stock Ownership Trust Note Agreement dated as of June 1, 1989, as amended. (Registrant hereby incorporates by reference Exhibit 4-B (b) to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2000, File No. 1-644-2.)
10-A
Colgate-Palmolive Company Executive Incentive Compensation Plan, amended and restated as of March 11, 1999. (Registrant hereby incorporates by reference Appendix A to its 1999 Notice of Meeting and Proxy Statement.)
Colgate-Palmolive Company Executive Incentive Compensation Plan Trust, as amended. (Registrant hereby incorporates by reference Exhibit 10-B (b) to its Annual Report on Form 10-K for the year ended December 31, 1987, File No. 1-644-2.)
10-B
Colgate-Palmolive Company Supplemental Salaried Employees Retirement Plan. (Registrant hereby incorporates by reference Exhibit 10-E (Plan only) to its Annual Report on Form 10-K for the year ended December 31, 1984, File No. 1-644-2.)
Colgate-Palmolive Company Supplemental Salaried Employees Retirement Plan Trust. (Registrant hereby incorporates by reference Exhibit 10-C (b) to its Annual Report on Form 10-K for the year ended December 31, 1987, File No. 1-644-2.)
10-C
Colgate-Palmolive Company Executive Severance Plan, as amended and restated. (Registrant hereby incorporates by reference Exhibit 10-E (a) to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2001, File No. 1-644.)
Colgate-Palmolive Company Executive Severance Plan Trust. (Registrant hereby incorporates by reference Exhibit 10-E (b) to its Annual Report on Form 10-K for the year ended December 31, 1987, File No. 1-644-2.)
10-D
Colgate-Palmolive Company Pension Plan for Outside Directors, as amended and restated. (Registrant hereby incorporates by reference Exhibit 10-D to its Annual Report on Form 10-K for the year ended December 31, 1999, File No. 1-644-2.)
10-E
Colgate-Palmolive Company Stock Plan for Non-Employee Directors, as amended.
10-F
Colgate-Palmolive Company Restated and Amended Deferred Compensation Plan for Non-Employee Directors, as amended. (Registrant hereby incorporates by reference Exhibit 10-H to its Annual Report on Form 10-K for the year ended December 31, 1997, File No. 1-644.)
10-G
Career Achievement Plan. (Registrant hereby incorporates by reference Exhibit 10-I to its Annual Report on Form 10-K for the year ended December 31, 1986, File No. 1-644-2.)
10-H
Colgate-Palmolive Company 1987 Stock Option Plan, as amended. (Registrant hereby incorporates by reference Exhibit 10-J to its Annual Report on Form 10-K for the year ended December 31, 1997, File No. 1-644.)
10-I
Stock Incentive Agreement between Colgate-Palmolive Company and Reuben Mark, Chairman and Chief Executive Officer, dated January 13, 1993, pursuant to the Colgate-Palmolive Company 1987 Stock Option Plan, as amended. (Registrant hereby incorporates by reference Exhibit 10-N to its Annual Report on Form 10-K for the year ended December 31, 1993, File No. 1-644-2.)
Stock Incentive Agreement between Colgate-Palmolive Company and Reuben Mark, Chairman and Chief Executive Officer, dated November 7, 1997, pursuant to the Colgate-Palmolive Company 1997 Stock Option Plan. (Registrant hereby incorporates by reference Exhibit 10-K(b) to its Annual Report on Form 10-K for the year ended December 31, 1997, File No. 1-644.)
10-J
Colgate-Palmolive Company Non-Employee Director Stock Option Plan, as amended. (Registrant hereby incorporates by reference Exhibit 10-L to its Annual Report on Form 10-K for the year ended December 31, 1997, File No. 1-644.)
10-K
U.S. $1,250,000,000 Five Year Credit Agreement dated as of May 10, 2002. (Registrant hereby incorporates by reference Exhibit 10-N to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2002,
File No. 1-644.)
10-L
Colgate-Palmolive Company 1996 Stock Option Plan, as amended. (Registrant hereby incorporates by reference Exhibit 10-N to its Annual Report on Form 10-K for the year ended December 31, 1997, File No. 1-644.)
10-M
Colgate-Palmolive Company 1997 Stock Option Plan. (Registrant hereby incorporates by reference appendix A to its 1997 Notice of Meeting and Proxy Statement.)
10-N
Description of the Colgate-Palmolive Company Supplemental Savings & Investment Plan.
Statement Computation of Ratio of Earnings to Fixed Charges.
Subsidiaries of the Registrant.
23-A
Consent of Independent Accountants.
23-B
Consent of Independent Public Accountants.
Powers of Attorney.
99-A
Certificate of the Chairman and Chief Executive Officer of Colgate-Palmolive Company pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
99-B
Certificate of the Chief Financial Officer of Colgate-Palmolive Company pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
The exhibits indicated above that are not included with the Form 10-K are available upon request and payment of a reasonable fee approximating the registrants cost of providing and mailing the exhibits. Inquiries should be directed to:
Colgate-Palmolive Company
Office of the Secretary (10-K Exhibits)
300 Park Avenue
New York, New York 10022-7499